Why Are Clinical Trials Important for Advancing Retinal Care?
The way clinicians diagnose and treat retinal conditions has changed significantly over the years, largely because of advances in medical research. Behind every approved therapy are years of structured studies that tested whether a new approach was safe and effective and how it compared with the care available at the time. In fact, many of today's retinal treatments, such as eye injections or laser therapy, have been evaluated and refined through clinical research.
While these advances have helped preserve and improve vision for countless patients, there is still much to learn about retinal diseases and how best to treat them. Clinical trials play a central role in this progress. At Mid Atlantic Retina Specialists, we are proud to participate in ongoing research and allow eligible patients to contribute to discoveries that may improve outcomes for both themselves and future generations.
What Is a Clinical Trial?
A clinical trial is a carefully designed research study involving volunteers that evaluates the safety and effectiveness of a medical treatment, procedure, or diagnostic approach.
Before an investigational drug or device is tested in patients, it typically goes through years of laboratory and preclinical work. Human studies then usually move through a series of phases:
- Phase 1 studies enroll a small number of people and focus primarily on safety and dosing.
- Phase 2 studies include a larger group and look for early evidence that the treatment works, while continuing to monitor side effects.
- Phase 3 studies may enroll hundreds or thousands of participants and compare the investigational treatment against the current standard of care or a control.
Every study is reviewed by an institutional review board (IRB), an independent committee responsible for protecting the rights and welfare of participants.
How Clinical Trials Shaped Today’s Retinal Care
Much of what retina specialists now consider routine care was once experimental. For example, anti-VEGF injections transformed the treatment of wet AMD in the mid-2000s, following clinical trials demonstrating their ability to slow vision loss and, in some patients, improve vision. Before anti-VEGF therapy, available treatments could help slow vision loss in certain patients, but improvements in vision were uncommon. Today, anti-VEGF injections are also the standard treatment for several other retinal conditions, including diabetic retinopathy.
More recently, in 2023, the FDA approved the first therapies shown to slow the progression of geographic atrophy (GA). Before, there was no treatment for GA, an advanced form of dry AMD.
Continuing the Advancement of Retinal Care
Even after a treatment is approved, research continues. Many studies focus on making existing treatments more effective, longer-lasting, or easier for patients to manage. For example, patients with wet AMD or diabetic macular edema (DME) may need injections as often as every four to eight weeks, depending on treatment and individual response, which can be difficult to sustain over years.
To reduce treatment burden, while maintaining or even maximizing the benefits, researchers are investigating:
- Longer-lasting treatments: Developing medications and delivery methods that can control retinal disease for extended periods, potentially reducing the frequency of treatments.
- Improved treatment effectiveness: Evaluating new therapies or combinations of treatments that may provide better outcomes for patients who do not respond adequately to existing options.
- Greater treatment safety: Studying potential side effects and identifying approaches that may reduce treatment-related risks.
- More individualized care: Learning which treatments work best for different patients based on their condition, disease severity, and response to therapy.
How Patients Contribute to Retinal Research
Every advancement has depended on patients who voluntarily participate in research. By joining a study, patients help researchers gather the information needed to evaluate new therapies and potentially improve care for others living with similar retinal conditions.
Depending on the study, participation may also provide access to investigational treatments and additional monitoring. However, these treatments are still being evaluated, and individual participants may not experience a direct medical benefit.
What Does Participating in a Clinical Trial Involve?
Each clinical trial has specific eligibility requirements, which may depend on factors such as a patient's diagnosis, medical history, previous treatments, and current retinal health.
Patients who qualify may be asked to attend scheduled study visits, undergo retinal imaging or other diagnostic tests, and follow a treatment or monitoring schedule established by the research team.
Before enrolling, patients receive information about the study's purpose, potential risks and benefits, and what participation would require. This process, known as informed consent, allows patients to ask questions and make an informed decision about whether to participate. Participation is entirely voluntary, and patients can withdraw from a clinical trial at any time.
Clinical Research at Mid Atlantic Retina Specialists
At Mid Atlantic Retina Specialists, research is an important part of our commitment to providing comprehensive, forward-thinking retinal care. Our physicians actively participate in clinical studies investigating new treatment options for diseases such as wet AMD, geographic atrophy, diabetic retinopathy, and diabetic macular edema.
If you are interested in participating in a clinical trial, ask your retina specialist about whether you may qualify, or call our office at (301) 671-2400.